Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	118.32	151.89
Short-Term Investments	277.14	0
Cash & Cash Equivalents	395.46	151.89
Cash Growth	160.36%	-
Other Current Assets	2.95	0.17
Total Current Assets	398.41	152.06
Property, Plant & Equipment	2.59	0
Other Long-Term Assets	0.4	0
Total Long-Term Assets	3	0
Total Assets	401.4	152.06
Accounts Payable	2.14	0.42
Current Debt	1.1	0
Other Current Liabilities	17.31	9.56
Total Current Liabilities	20.56	9.98
Long-Term Debt	0.93	0
Total Long-Term Liabilities	0.93	0
Total Liabilities	21.49	9.98
Total Debt	2.03	0
Retained Earnings	-123.77	-39.79
Comprehensive Income	0.33	0
Shareholders' Equity	379.91	-35.39
Net Cash / Debt	393.43	151.89
Net Cash / Debt Growth	159.02%	-
Net Cash Per Share	15.73	61.69
Working Capital	377.85	142.08
Book Value Per Share	15.19	-14.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).